Maysa Vilbert
Overview
Explore the profile of Maysa Vilbert including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
27
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Michelon I, Castro C, Madeira T, Dacoregio M, Stecca C, Soares L, et al.
Cancer Treat Rev
. 2025 Jan;
133:102882.
PMID: 39805165
Background: Trastuzumab deruxtecan (T-DXd) has shown promising activity in patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer (BC) and central nervous system (CNS) involvement. In this updated...
2.
Vilbert M, Zubiri L, Mooradian M, Reynolds K
JCO Oncol Pract
. 2024 Dec;
21(3):270-272.
PMID: 39700457
No abstract available.
3.
Ravani L, Calomeni P, Vilbert M, Madeira T, Wang M, Deng D, et al.
JCO Oncol Pract
. 2024 Dec;
:OP2400649.
PMID: 39689274
Purpose: Cyclin-dependent kinase 4/6 inhibitors (CDK4/6is) combined with endocrine therapy (ET) are the standard of care in hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer (aBC). Yet,...
4.
Dacoregio M, Michelon I, Ernesto do Rego Castro C, de Moraes F, Rossato de Almeida G, Ravani L, et al.
Breast
. 2024 Dec;
79:103853.
PMID: 39616817
Background: Sacituzumab Govitecan (SG), a first-in-class anti-trophoblast cell surface antigen-2-directed antibody-drug conjugate (ADC), has shown clinically meaningful improvement in outcomes of patients with breast cancer (BC). However, it has also...
5.
Priantti J, Fujiwara Y, de Moraes F, Michelon I, Castro C, Leighl N, et al.
JCO Precis Oncol
. 2024 Nov;
8:e2400331.
PMID: 39576954
Purpose: The activity of osimertinib is not fully characterized in non-small-cell lung cancer (NSCLC) with uncommon epidermal growth factor receptor () mutations. Therefore, we conducted a systematic review and meta-analysis...
6.
Michelon I, Dacoregio M, Vilbert M, Priantti J, Ernesto do Rego Castro C, Vian L, et al.
Ther Adv Med Oncol
. 2024 Nov;
16:17588359241297079.
PMID: 39574495
Background: Until recently, targeted therapies have failed to benefit patients with human epidermal growth factor receptor 2 (HER2)-low-expressing breast cancer (BC). Nevertheless, antibody-drug conjugates (ADCs) have reshaped their prognosis. Objectives:...
7.
Mesquita Y, Marques I, Pera Calvi I, Cruz S, Godoi A, Lapenda I, et al.
J Eur Acad Dermatol Venereol
. 2024 Nov;
39(3):566-575.
PMID: 39548723
Background: Melanoma of the lentigo maligna (LM) type and its invasive counterpart, lentigo maligna melanoma (LMM), occur in chronically sun-damaged skin and tend to have subclinical extension that makes presurgical...
8.
Dacoregio M, Abrahao Reis P, Celso D, Romero L, Altmayer S, Vilbert M, et al.
Eur Radiol
. 2024 Jul;
35(2):643-651.
PMID: 39075300
Objectives: Li-Fraumeni syndrome (LFS) is a cancer syndrome associated with early-onset neoplasias. The use of whole-body magnetic resonance imaging (WBMRI) is recommended for regular cancer screening, however, evidence supporting the...
9.
Michelon I, Vilbert M, Ernesto do Rego Castro C, Stecca C, Dacoregio M, Rizzo M, et al.
J Pers Med
. 2024 Jul;
14(7).
PMID: 39064005
We performed a systematic review and meta-analysis to assess the efficacy of EGFR-tyrosine kinase inhibitors (TKI) retreatment in advanced/metastatic non-small-cell lung cancer (NSCLC) patients. We systematically searched PubMed, Embase, Cochrane...
10.
Priantti J, Vilbert M, de Moraes F, Madeira T, de Lima Santiago E, Leighl N, et al.
Cancers (Basel)
. 2024 Jul;
16(14).
PMID: 39061249
Lorlatinib has been FDA-approved as a systemic therapy for ALK/ROS1-positive non-small cell lung cancer (NSCLC) patients. However, it has been associated with an increased frequency of neurocognitive adverse events (NAEs)....